SCHEMBL4772157

SCHEMBL4772157

CCCC[Sn](CCCC)(CCCC)c1ccc(CC(C)C(=O)OC)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.38
ESR2 Q92731 1/20 0.38
BIRC2 Q13490 1/20 0.37
ALDH1A1 P00352 1/20 0.36
THRB P10828 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ACACB O00763 2/20 0.36
EPHX2 P34913 1/20 0.36
PPARG P37231 1/20 0.36
POLB P06746 1/20 0.36
PTPRB P23467 1/20 0.35
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CXCR1 P25024 1/20 0.34
CXCR2 P25025 1/20 0.34
MIF P14174 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7454243 0.81 NPC1 (0.50) ALDH1A1THRBHSD17B10POLBTAS1R3
SCHEMBL7250202 0.79 ESR1 (0.44) ESR1ESR2ALDH1A1THRBCYP2C9
SCHEMBL2720546 0.77 KLK5 (0.49) BIRC2POLB
SCHEMBL2480406 0.77 KLK5 (0.49) BIRC2POLB
SCHEMBL13534766 0.77 ESR1 (0.47) ESR1ESR2ALDH1A1THRBCYP2C9
SCHEMBL5952565 0.76 NPC1 (0.50) ALDH1A1POLBCA1CA2
SCHEMBL28446209 0.76 CYP4A11 (0.48) ALDH1A1CA1CA2
SCHEMBL5546946 0.74 ESR1 (0.65) ESR1ESR2CA1CA2MIF
SCHEMBL14590363 0.74 ATM (0.50) ESR1ESR2ALDH1A1THRBCYP2C9
SCHEMBL15314148 0.74 ESR1 (0.65) ESR1ESR2CA1CA2MIF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 ESR1 4147/4885ESR2 4247/4885BIRC2 2908/4885
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 ESR1 4583/4885ESR2 4091/4885BIRC2 3709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.